Insider Brief
- Plexision has received a $365,000 investment from the Richard King Mellon Foundation to enhance AI- and ML-driven blood tests to predict complex transplant outcomes.
- The company's platform integrates immune cell function with machine learning to rank the risk of rejection and infection, allowing faster and more accurate clinical decisions within 6-24 hours.
- Tests like Plexision's Plexision's PlexAbmr™ and PlexeBV™, tested through Multi-Center research, have shown strong prediction accuracy and will be featured at the 2025 World Transplant Conference.
Press Release – Biotechnology company Plexision has announced a $365,000 investment from the Richard Kingmelon Foundation. The funding will be used to accelerate the integration of artificial intelligence (AI) and machine learning (ML) features across Plexision's cell-based blood test suite, significantly improving the predictive accuracy of complex implantation results.
Despite advances in transplant medicine, the management of immunosuppressive drugs remains a delicate balance. Too fewer drugs can be antibody-mediated or antibody-mediated, but in many cases it can increase the risk of lymphoma associated with different viruses, and in some cases Epstein-BARR virus (EBV). Market legacy testing tools provide limited visibility into a patient's immune status and provide reactive binary results. To distinguish between different types of rejection and infection, clinicians often combine other clinical data to make treatment decisions.
Plexision blood tests predict the most common rejection subtypes and post-transplant infections, all using a general platform for immune cell function. When integrated with machine learning, this test panel ranks the risks of multiple outcomes across each patient outcome category, including the possibility of stable graft function, T-cell-mediated and antibody-mediated rejection. This approach identifies the presence or absence of infections, including infection-related lymphomas. These capabilities have been developed and verified in multicenter research reported at the World Transplant Conference in San Francisco, California between August 2-6, 2025.
“We are a scientist who has a surgeon, and a surgeon, and a surgeon, and a scientist, and Plexision,” said Dr. Rakesh Sindhi, Plexision, co-founder and chief science officer.
The expansion of AI use enhances the platform's ability to rank and predict the potential for multiple outcomes for each patient, making it a powerful clinical decision support tool for caregivers who provide precision transplant care. The company's unique technology allows for just 6-24 hours of results, allowing timely intervention.
“This funding allows us to take the next step to truly personalize transplant care. By expanding our artificial intelligence and machine learning capabilities, we are shifting from a 'yes/no' response to move towards tailored predictions for each patient, moving from an 'yes/no' response to tailored predictions for each patient,” added Cindy.
All tests are performed at a CLIA-approved and cap-certified reference laboratory at Plxision, Pittsburgh, PA, using blood samples shipped from clinical partners. The results will be used together with other clinical data to optimize management of individual transplant patients.
Plexision's innovation demonstrates strong clinical performance. For example, the company's PlexABMR™ test recently predicted antibody-mediated rejection in kidney transplant recipients with 81% positive predictors and 75% negative predictors in multi-center tests. Another test predicted EBV infection, a cause of life-threatening infection-related lymphoma in transplant patients. These findings will also be featured at the 2025 World Transplant Conference.
For more information about Plexision, please visit https://plexision.com/ [email protected] Schedule a meeting with your company at the World Transplant Conference.
About Plexision
Plexision's Reference Institute performs cell-based blood tests for personalized management of transplant rejection, infection of immunodeficiency patients, and immunotherapy in oncology. Transplant Rejection Test Services include FDA-approved Pleximun™ blood tests to predict transplant rejection in children with liver or bowel transplants, laboratory-developed Pleximark™ tests to predict kidney transplant rejection, and the recently developed PlexABMR™ predict antibody-mediated rejection. Tests that predict infection include Lab's development's PlexCMV™, the most sensitive test to capture protective cell-mediated immunity in high-CMV risk transplantation. The PlexeBV™ test predicts EBV infections that can cause post-transplant lymphoma. These tests measure cell-mediated immunity against cytomegalovirus and EBV, respectively. Plexision also runs custom R&D projects that require integration of cell biomarker targets at every stage of drug, vaccine and gene therapy product development, from pre-clinical to post-marketing. The company's portfolio of cell-based blood tests can be adapted to assess disease risks for several immune disorders and develop personalized dosing recommendations. The company's reference laboratory in Pittsburgh, Pennsylvania is CLIA approved, cap certified and GMP compliant. For more information, please visit www.plexision.com or email [email protected].
About the Richard Kingmelon Foundation
Founded in 1947, the Richard Kingmelon Foundation is the largest foundation in southwestern Pennsylvania and the largest 50 people in the world. The foundation's end-of-year net worth was $2.9 billion, with the 2023 trustee paying more than $176 million in grants and program-related investments. The Foundation concentrates funding in six major program areas depicted in its 2021-2030 strategic plan.
contact address
Jason Bankra
Plexision's Marketbridge
[email protected]
sauce
